Focused On-demand Library for POU domain, class 3, transcription factor 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P49335

UPID:

PO3F4_HUMAN

Alternative names:

Brain-specific homeobox/POU domain protein 4; Octamer-binding protein 9; Octamer-binding transcription factor 9

Alternative UPACC:

P49335; B2RC71; Q5H9G9; Q99410

Background:

POU domain, class 3, transcription factor 4 (POU3F4), also known as Brain-specific homeobox/POU domain protein 4, Octamer-binding protein 9, and Octamer-binding transcription factor 9, plays a pivotal role in early neural development and maintains specific functions in a limited set of neurons in the adult brain. Its unique position in neural development pathways underscores its importance in cellular differentiation and maturation processes.

Therapeutic significance:

POU3F4 is directly implicated in Deafness, X-linked, 2, a condition characterized by conductive hearing loss and progressive sensorineural deafness. This association highlights the protein's critical role in auditory function and presents a targeted opportunity for therapeutic intervention in genetic hearing loss disorders.